CN116239610A - Pyrimidine derivative, preparation method thereof and application thereof in preparation of antitumor drugs - Google Patents
Pyrimidine derivative, preparation method thereof and application thereof in preparation of antitumor drugs Download PDFInfo
- Publication number
- CN116239610A CN116239610A CN202310154871.8A CN202310154871A CN116239610A CN 116239610 A CN116239610 A CN 116239610A CN 202310154871 A CN202310154871 A CN 202310154871A CN 116239610 A CN116239610 A CN 116239610A
- Authority
- CN
- China
- Prior art keywords
- pyrimidine derivative
- cancer
- acid
- pharmaceutically acceptable
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003230 pyrimidines Chemical class 0.000 title claims abstract description 56
- 239000002246 antineoplastic agent Substances 0.000 title claims abstract description 17
- 229940041181 antineoplastic drug Drugs 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 17
- 229920006395 saturated elastomer Polymers 0.000 claims abstract description 9
- -1 cyano, amino Chemical group 0.000 claims abstract description 7
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 4
- 150000002367 halogens Chemical class 0.000 claims abstract description 4
- 125000001424 substituent group Chemical group 0.000 claims abstract description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 14
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 7
- 229940124597 therapeutic agent Drugs 0.000 claims description 7
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 108010006654 Bleomycin Proteins 0.000 claims description 5
- 229960001561 bleomycin Drugs 0.000 claims description 5
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 5
- 208000029742 colonic neoplasm Diseases 0.000 claims description 5
- 229960004679 doxorubicin Drugs 0.000 claims description 5
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 4
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims description 4
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 4
- 229960000303 topotecan Drugs 0.000 claims description 4
- 208000032612 Glial tumor Diseases 0.000 claims description 3
- 206010018338 Glioma Diseases 0.000 claims description 3
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims description 3
- 229960000397 bevacizumab Drugs 0.000 claims description 3
- 229960004562 carboplatin Drugs 0.000 claims description 3
- 229960004316 cisplatin Drugs 0.000 claims description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- HAWSQZCWOQZXHI-FQEVSTJZSA-N 10-Hydroxycamptothecin Chemical compound C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-FQEVSTJZSA-N 0.000 claims description 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 2
- FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 claims description 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 2
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 2
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims description 2
- 239000003798 L01XE11 - Pazopanib Substances 0.000 claims description 2
- 239000002118 L01XE12 - Vandetanib Substances 0.000 claims description 2
- 108010000817 Leuprolide Proteins 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000000172 Medulloblastoma Diseases 0.000 claims description 2
- 229930192392 Mitomycin Natural products 0.000 claims description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 229960003437 aminoglutethimide Drugs 0.000 claims description 2
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 2
- 229960002170 azathioprine Drugs 0.000 claims description 2
- 229960002092 busulfan Drugs 0.000 claims description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 2
- 229960004117 capecitabine Drugs 0.000 claims description 2
- 229960005243 carmustine Drugs 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 229960004397 cyclophosphamide Drugs 0.000 claims description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 2
- 229960000975 daunorubicin Drugs 0.000 claims description 2
- NYDXNILOWQXUOF-UHFFFAOYSA-L disodium;2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioate Chemical compound [Na+].[Na+].C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)NC(CCC([O-])=O)C([O-])=O)C=C1 NYDXNILOWQXUOF-UHFFFAOYSA-L 0.000 claims description 2
- 229960003668 docetaxel Drugs 0.000 claims description 2
- 229950005454 doxifluridine Drugs 0.000 claims description 2
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 229960001904 epirubicin Drugs 0.000 claims description 2
- 229960001433 erlotinib Drugs 0.000 claims description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 2
- 229960005167 everolimus Drugs 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 229960002258 fulvestrant Drugs 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 229960002584 gefitinib Drugs 0.000 claims description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 229960005277 gemcitabine Drugs 0.000 claims description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 229940022353 herceptin Drugs 0.000 claims description 2
- 229960002411 imatinib Drugs 0.000 claims description 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 2
- 229960005386 ipilimumab Drugs 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 229960004891 lapatinib Drugs 0.000 claims description 2
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims description 2
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims description 2
- 229960003881 letrozole Drugs 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 claims description 2
- 229960004338 leuprorelin Drugs 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 229960004961 mechlorethamine Drugs 0.000 claims description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 229960001428 mercaptopurine Drugs 0.000 claims description 2
- 229960000485 methotrexate Drugs 0.000 claims description 2
- 229960004857 mitomycin Drugs 0.000 claims description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 2
- 229960001156 mitoxantrone Drugs 0.000 claims description 2
- 229960001420 nimustine Drugs 0.000 claims description 2
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 claims description 2
- 229960003301 nivolumab Drugs 0.000 claims description 2
- 229960001756 oxaliplatin Drugs 0.000 claims description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 229960000639 pazopanib Drugs 0.000 claims description 2
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims description 2
- 229960003349 pemetrexed disodium Drugs 0.000 claims description 2
- 229960001221 pirarubicin Drugs 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 229960004641 rituximab Drugs 0.000 claims description 2
- 229960003440 semustine Drugs 0.000 claims description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 206010042863 synovial sarcoma Diseases 0.000 claims description 2
- 239000000454 talc Substances 0.000 claims description 2
- 229910052623 talc Inorganic materials 0.000 claims description 2
- 229960001603 tamoxifen Drugs 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- 229960003087 tioguanine Drugs 0.000 claims description 2
- 229960000575 trastuzumab Drugs 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 229960000241 vandetanib Drugs 0.000 claims description 2
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 claims description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 2
- 239000008158 vegetable oil Substances 0.000 claims description 2
- 229960002066 vinorelbine Drugs 0.000 claims description 2
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- 229940034982 antineoplastic agent Drugs 0.000 claims 4
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- 239000005660 Abamectin Substances 0.000 claims 1
- 229960004607 alfuzosin Drugs 0.000 claims 1
- WNMJYKCGWZFFKR-UHFFFAOYSA-N alfuzosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CCCNC(=O)C1CCCO1 WNMJYKCGWZFFKR-UHFFFAOYSA-N 0.000 claims 1
- RRZXIRBKKLTSOM-XPNPUAGNSA-N avermectin B1a Chemical compound C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 RRZXIRBKKLTSOM-XPNPUAGNSA-N 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 235000019634 flavors Nutrition 0.000 claims 1
- 229960001101 ifosfamide Drugs 0.000 claims 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229960003171 plicamycin Drugs 0.000 claims 1
- 229920005862 polyol Polymers 0.000 claims 1
- 150000003077 polyols Chemical class 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 24
- 230000005764 inhibitory process Effects 0.000 abstract description 11
- 238000001959 radiotherapy Methods 0.000 abstract description 11
- 238000002512 chemotherapy Methods 0.000 abstract description 10
- 229940079593 drug Drugs 0.000 abstract description 9
- 230000004614 tumor growth Effects 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 28
- 108010006124 DNA-Activated Protein Kinase Proteins 0.000 description 26
- 102000005768 DNA-Activated Protein Kinase Human genes 0.000 description 22
- 150000001875 compounds Chemical class 0.000 description 13
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 13
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 8
- 229940126289 DNA-PK inhibitor Drugs 0.000 description 7
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- XISVSTPEXYIKJL-UHFFFAOYSA-N 7-methyl-2-[(7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-(oxan-4-yl)purin-8-one Chemical compound CN1C(=O)N(C2CCOCC2)C2=NC(NC3=CN4N=CN=C4C=C3C)=NC=C12 XISVSTPEXYIKJL-UHFFFAOYSA-N 0.000 description 6
- 229940126288 AZD7648 Drugs 0.000 description 6
- 102100022204 DNA-dependent protein kinase catalytic subunit Human genes 0.000 description 6
- 101710157074 DNA-dependent protein kinase catalytic subunit Proteins 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 231100000263 cytotoxicity test Toxicity 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical class C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 206010003571 Astrocytoma Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 208000030883 malignant astrocytoma Diseases 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 102000008158 DNA Ligase ATP Human genes 0.000 description 2
- 108010060248 DNA Ligase ATP Proteins 0.000 description 2
- 230000005971 DNA damage repair Effects 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 102100036976 X-ray repair cross-complementing protein 6 Human genes 0.000 description 2
- 101710124907 X-ray repair cross-complementing protein 6 Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229960005419 nitrogen Drugs 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000011127 radiochemotherapy Methods 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 2
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- RBNPOMFGQQGHHO-UHFFFAOYSA-N -2,3-Dihydroxypropanoic acid Natural products OCC(O)C(O)=O RBNPOMFGQQGHHO-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- KWMLJOLKUYYJFJ-UHFFFAOYSA-N 2,3,4,5,6,7-Hexahydroxyheptanoic acid Chemical compound OCC(O)C(O)C(O)C(O)C(O)C(O)=O KWMLJOLKUYYJFJ-UHFFFAOYSA-N 0.000 description 1
- JAHNSTQSQJOJLO-UHFFFAOYSA-N 2-(3-fluorophenyl)-1h-imidazole Chemical compound FC1=CC=CC(C=2NC=CN=2)=C1 JAHNSTQSQJOJLO-UHFFFAOYSA-N 0.000 description 1
- YGTUPRIZNBMOFV-UHFFFAOYSA-N 2-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)C1=CC=C(O)C=C1 YGTUPRIZNBMOFV-UHFFFAOYSA-N 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-N 3-Hydroxy-2-naphthoate Chemical compound C1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- AWQSAIIDOMEEOD-UHFFFAOYSA-N 5,5-Dimethyl-4-(3-oxobutyl)dihydro-2(3H)-furanone Chemical compound CC(=O)CCC1CC(=O)OC1(C)C AWQSAIIDOMEEOD-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 238000003727 ADP Glo Kinase Assay Methods 0.000 description 1
- WDJHALXBUFZDSR-UHFFFAOYSA-N Acetoacetic acid Natural products CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 description 1
- QNZCBYKSOIHPEH-UHFFFAOYSA-N Apixaban Chemical compound C1=CC(OC)=CC=C1N1C(C(=O)N(CC2)C=3C=CC(=CC=3)N3C(CCCC3)=O)=C2C(C(N)=O)=N1 QNZCBYKSOIHPEH-UHFFFAOYSA-N 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- RBNPOMFGQQGHHO-UWTATZPHSA-N D-glyceric acid Chemical compound OC[C@@H](O)C(O)=O RBNPOMFGQQGHHO-UWTATZPHSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 102100027828 DNA repair protein XRCC4 Human genes 0.000 description 1
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102100030011 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 101000649315 Homo sapiens DNA repair protein XRCC4 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- UXRZLDREKITWRO-UHFFFAOYSA-N P(c1ccccc1)c1ccccc1.CC1(C)c2ccccc2Oc2ccccc12 Chemical class P(c1ccccc1)c1ccccc1.CC1(C)c2ccccc2Oc2ccccc12 UXRZLDREKITWRO-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241001660687 Xantho Species 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229960003886 apixaban Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000002619 bicyclic group Chemical class 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000000460 chlorine Chemical group 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 201000011024 colonic benign neoplasm Diseases 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- JBDSSBMEKXHSJF-UHFFFAOYSA-N cyclopentanecarboxylic acid Chemical compound OC(=O)C1CCCC1 JBDSSBMEKXHSJF-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- WOWBFOBYOAGEEA-UHFFFAOYSA-N diafenthiuron Chemical compound CC(C)C1=C(NC(=S)NC(C)(C)C)C(C(C)C)=CC(OC=2C=CC=CC=2)=C1 WOWBFOBYOAGEEA-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 230000005782 double-strand break Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052740 iodine Chemical group 0.000 description 1
- 239000011630 iodine Chemical group 0.000 description 1
- 238000010983 kinetics study Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000000504 luminescence detection Methods 0.000 description 1
- 238000002796 luminescence method Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- LVHBHZANLOWSRM-UHFFFAOYSA-N methylenebutanedioic acid Natural products OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- APNPVBXEWGCCLU-QNRZBPGKSA-N mycomycin Chemical compound OC(=O)C\C=C\C=C/C=C=CC#CC#C APNPVBXEWGCCLU-QNRZBPGKSA-N 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 150000004968 peroxymonosulfuric acids Chemical class 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 229950010773 pidilizumab Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 1
- 229960003089 pramipexole Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 150000003354 serine derivatives Chemical class 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000007761 synergistic anti-cancer Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the technical field of medicines, and discloses a pyrimidine derivative, a preparation method thereof and application thereof in preparing antitumor drugs. The structural general formula of the pyrimidine derivative is shown as (I); wherein X, Y and Z are each independently selected from CH, N; r is R 1 Selected from the following substituted or unsubstituted: c (C) 5 ‑C 12 Saturated or unsaturated carboheterocyclyl, C 5 ‑C 12 Saturated or unsaturated spiroheterocyclyl, C 5 ‑C 12 Saturated or unsaturated fused heterocyclic groups, wherein the substituents refer to one or more groups selected from the group consisting of: hydroxy, halogen, cyano, amino. The pyrimidine derivative has good DNA-PK inhibition activity and pharmacokinetics stability, can effectively inhibit tumor growth, and synergistically enhance the effects of chemotherapy and radiotherapy;
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to a pyrimidine derivative, a preparation method thereof and application thereof in preparing antitumor drugs.
Background
At present, clinical researches find that many tumor patients resist radiotherapy and chemotherapy, so that the search of low-toxicity high-efficiency targeted drugs and radiotherapy and chemotherapy sensitizers has important significance for tumor treatment formulas. The main mechanism of action of DNA damaging chemotherapeutics (e.g. bleomycin, topoisomerase II inhibitors such as etoposide and doxorubicin) and radiotherapy commonly used in tumor treatment at present is to cause lethal double strand break of DNA molecules, thereby inducing death of tumor cells. However, the existence of a DNA damage repair system in tumor cells, such as DNA-dependent protein kinase (DNA-dependent protein kinase, DNA-PK), can repair such breaks, thereby improving the viability of tumor cells, which is one of the mechanisms of tumor cells against chemoradiotherapy. Accordingly, the sensitivity of tumor cells to radiotherapy and chemotherapy can be improved only by inhibiting the repair of the DNA damage.
DNA-PK is a class of serine/threonine protein kinases that participate in and determine the overall process of connecting non-homologous ends to DNA damage repair pathways. DNA-PK is a complex consisting of catalytic subunits DNA-PKcs and Ku70/80 heterodimers, wherein the Ku70/80 heterodimers recognize DNA breaks (DSBs) and recruit activated kinase subunits DNA-PKcs that direct Artemis binding to the site of injury, followed by recruitment and binding of the XRCC4/DNA-Ligase IV complex by the activated DNA-PKcs and finally localization and ligation of broken DNA double stranded ends by DNA-Ligase IV, thereby completing the entire repair process. Research shows that high expression of DNA-PK is found in tumor tissues treated by radiotherapy and chemotherapy, and the increase of the activity of DNA-PKcs enhances the repair of damaged DNA to a certain extent, prevents death of tumor cells and leads to tolerance to radiotherapy and chemotherapy. In addition, cells surviving tumor tissues after radiotherapy and chemotherapy are often cells with high DNA-PKcs activity insensitive to treatment, which is also the reason of poor curative effect and poor prognosis. The DNA-PK inhibitor can inhibit the activity of DNA-PKcs by being combined with a chemoradiotherapy medicament, thereby greatly reducing the DNA repair of tumors and inducing cells to enter an apoptosis program so as to achieve better treatment effect.
Accordingly, the present invention contemplates novel compounds having DNA-PK (DNA-dependent protein kinase) inhibiting function for better application in the treatment of tumors.
Disclosure of Invention
The present invention aims to solve at least one of the technical problems in the prior art described above. Therefore, the invention provides a pyrimidine derivative, a preparation method thereof and application thereof in preparing antitumor drugs. The pyrimidine derivative has good DNA-PK inhibition activity and pharmacokinetics stability, can effectively inhibit tumor growth, and synergistically enhances the effects of chemotherapy and radiotherapy.
The invention provides a pyrimidine derivative or pharmaceutically acceptable salt and stereoisomer thereof, wherein the structural general formula of the pyrimidine derivative is shown as (I):
wherein X, Y and Z are each independently selected from CH, N; r is R 1 Selected from the following substituted or unsubstituted: c (C) 5 -C 12 Saturated or unsaturated carboheterocyclyl, C 5 -C 12 Saturated or unsaturated spiroheterocyclyl, C 5 -C 12 Saturated or unsaturated fused heterocyclic groups, wherein the substituents refer to one or more groups selected from the group consisting of: hydroxy, halogen, cyano, amino.
The pharmaceutically acceptable salts of the pyrimidine derivatives of the invention may be: acid addition salts with acids which carry nitrogen atoms in the chain or ring, acid addition salts with inorganic acids (e.g. hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, resulfuric acid, phosphoric acid or nitric acid), acid addition salts with organic acids (e.g. formic acid, acetic acid, acetoacetic acid, pyruvic acid, trifluoroacetic acid, propionic acid, butyric acid, caproic acid, heptanoic acid, undecanoic acid, lauric acid, benzoic acid, salicylic acid, 2- (4-hydroxybenzoyl) -benzoic acid, camphoric acid, cinnamic acid, cyclopentanic acid, digluconic acid, 3-hydroxy-2-naphthoic acid, nicotinic acid, pamoic acid, pectic acid, persulfuric acid, 3-phenylpropionic acid, picric acid, pivalic acid, 2-hydroxyethanesulfonic acid, itaconic acid, sulfamic acid, trifluoromethanesulfonic acid, dodecylsulfuric acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, methanesulfonic acid, 2-naphthalenesulfonic acid, naphthalenedisulfonic acid, camphorsulfonic acid, citric acid, tartaric acid, stearic acid, lactic acid, oxalic acid, malonic acid, succinic acid, malic acid, adipic acid, maleic acid, fumaric acid, D-gluconic acid, heptonic acid, glyceric acid, salicylic acid, sulfuric acid, semi-sulfuric acid or sulfuric acid.
Preferably, said R 1 Selected from the following groups:
preferably, the pyrimidine derivative is selected from the following compounds:
the invention also provides a preparation method of the pyrimidine derivative, and the synthetic method is as follows:
in the above synthesis method, the first step is to use R for hydrogen in Z 1 The group is substituted, and the second step is to substitute on chlorine atom to prepare the final pyrimidine derivative.
The invention also provides application of the pyrimidine derivative or the pharmaceutically acceptable salt and stereoisomer thereof in preparing antitumor drugs. The pyrimidine derivative or pharmaceutically acceptable salt and stereoisomer thereof has the effect of inhibiting DNA-PK (DNA dependent protein kinase), and can be used for preventing and/or treating DNA-PK mediated diseases such as tumor.
Preferably, the tumor is selected from colon cancer, lung cancer, ovarian cancer, endometrial cancer, pancreatic cancer, head and neck cancer, esophageal cancer, breast cancer, colorectal cancer, lymphoma, leukemia, synovial sarcoma, melanoma, liver cancer, gastric cancer, bladder cancer, squamous cell carcinoma, medulloblastoma, renal cancer or glioma.
The invention provides an antitumor drug, which comprises the pyrimidine derivative or pharmaceutically acceptable salt and stereoisomer thereof as a first therapeutic agent. The antitumor drug can be used in combination with chemotherapy or radiotherapy (such as X-ray, gamma ray, and radiopharmaceuticals), and has good synergistic anticancer effect.
Preferably, the antitumor drug further comprises pharmaceutically acceptable auxiliary materials.
More preferably, the pharmaceutically acceptable adjuvant comprises cellulose and its derivatives (such as sodium carboxymethylcellulose, sodium ethylcellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (such as stearic acid, magnesium stearate), calcium sulfate, vegetable oils (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyalcohols (such as propylene glycol, glycerol, mannitol, sorbitol, etc.), emulsifying agentAt least one of a wetting agent (such as sodium lauryl sulfate), a coloring agent, a flavoring agent, a stabilizing agent, an antioxidant, a preservative, or water.
Preferably, the antitumor drug further comprises a second therapeutic agent, the second therapeutic agent is selected from the group consisting of oxidastine, lu Kapa, nilapamide, methotrexate, capecitabine, gemcitabine, doxifluridine, pemetrexed disodium, pazopanib, imatinib, erlotinib, lapatinib, gefitinib, vandetanib, herceptin, bevacizumab, rituximab, trastuzumab, paclitaxel, vinorelbine, docetaxel, doxorubicin, hydroxycamptothecin, mitomycin, epirubicin, pirarubicin, bleomycin, letrozole, tamoxifen, fulvestrant, trastulin, fluzamide, leuprolide, azalide, busulfan, cyclophosphamide, mitoxantine at least one of carmustine, nimustine, semustine, nitrogen mustard, horse flange, onconine, carboplatin, cisplatin, oxaliplatin, carboplatin, topotecan, camptothecine, topotecan, everolimus, siromosi, tertiarycancer aptamer, 6-mercaptopurine, 6-thioguanine, azathioprine, mycomycin D, daunorubicin, doxorubicin, mitoxantrone, bleomycin, pramipexole or aminoglutethimide, nivolumab, pembrolizumab, ipilimumab, bevacizumab, dulvacizumab, at Zhu Shankang (atezolizumab), and Pidilizumab. The second therapeutic agent with anticancer effect can be added into the antitumor drug to inhibit tumor growth more effectively.
Unless otherwise indicated, the following terms appearing in the present invention have the following meanings:
the term "halogen", "halo" refers to fluorine, chlorine, bromine or iodine.
The term "carboheterocyclyl" refers to a cyclic alkyl group containing a specified number of heteroatoms including carbon atoms and 1, 2, 3 or 4 heteroatoms, especially nitrogen, oxygen and/or sulfur, wherein the heteroatoms are the same or different, which may be monocyclic (e.g., C 5 -C 10 Cycloalkyl) may also be in the form of a bicyclic or tricyclic ring, such as bridged, fused or spiro ring (e.g., C 5 -C 10 Bridged cycloalkyl, C 5 -C 10 Condensed ring alkyl, C 5 -C 10 Spirocycloalkyl) forms.
The term "substituted" means that one or more hydrogens on the designated atom are replaced with a selection from the indicated groups, provided that: no more than the normal valency of the atom specified in the prior art, and this substitution results in a stable compound. Substituents and/or variables may be combined so long as such combination can result in a stable compound.
Compared with the prior art, the invention has the following beneficial effects:
(1) The pyrimidine derivative has excellent DNA-PK inhibition effect, shows good pharmacokinetic property in organisms, and can synergistically enhance the effects of chemotherapy and radiotherapy, thereby playing a good role in resisting tumor.
(2) The pyrimidine derivative has the advantages of short synthetic route, simple preparation process and easy mass industrial production.
Detailed Description
In order to make the technical solutions of the present invention more apparent to those skilled in the art, the following examples will be presented. It should be noted that the following embodiments are only preferred embodiments of the present invention, and the scope of the present invention is not limited to the following embodiments, and any modifications, substitutions, and combinations made without departing from the spirit and principles of the present invention are included in the scope of the present invention.
The starting materials, reagents or apparatus used in the following examples are all available from conventional commercial sources or may be obtained by methods known in the art unless otherwise specified.
Example 1
This example provides a pyrimidine derivative T-01, the synthetic route of which is shown below:
the preparation method comprises the following steps:
(1) To the reaction flask were added compound 1 (350 mg), tetrahydrofuran (10 mL), triphenylphosphine (972 mg) and compound 2 (241 mg), stirred and cooled to 0 ℃, diisopropyl azodicarboxylate DIAD (749 mg) was added dropwise, and after the addition, the mixture was heated to 70 ℃ and reacted for 16 hours, cooled, concentrated, purified by column chromatography on silica gel, ethyl acetate: petroleum ether system elution gives compound 3 (373 mg) as a pale yellow solid. LCMS: (MS-ESI, M/z) [ M+H ]] + =267。
(2) To the reaction flask were added compound 3 (25 mg), compound 4 (14 mg), palladium acetate (5 mg), cesium carbonate (61 mg), 4, 5-bis (diphenylphosphine) -9, 9-dimethylxanthenes Xanthos (6 mg) and dioxane (2 mL), and the mixture was stirred and heated to 100℃under nitrogen protection, reacted for 2 hours, cooled to 25℃and filtered, and the filtrate was subjected to reverse phase preparative liquid phase HPLC [ Waters Sunfire C18,10 μm,column,gradient 10-95% B(solvent A,0.02% TFA in water;solvent B,CH 3 CN)]purification gave white compound T-01 (2 mg).
Pyrimidine derivative T-01 was detected as follows:
LCMS:(MS-ESI,m/z):[M+H] + =379。 1 H NMR:(400MHz,DMSO-d6,ppm):δ8.92(s,1H),
8.87(s,1H),8.78(d,J=1.8Hz,1H),8.73(d,J=1.8Hz,1H),8.64(s,1H),8.41(s,1H),4.61(s,1H),3.98(s,2H),3.56(s,2H),2.55(s,3H),2.21(d,J=7.8Hz,2H),2.00(s,2H)。
example 2
This example provides a pyrimidine derivative T-02, which is synthesized in substantially the same manner as in example 1, except that:
Pyrimidine derivative T-02 was detected as follows:
LCMS:(MS-ESI,m/z):[M+H] + =349。 1 H NMR:(400MHz,DMSO-d6,ppm):δ8.81(s,1H),
8.72(dd,J=4.2,1.6Hz,1H),8.47(s,1H),8.34(s,1H),8.18(d,J=7.7Hz,1H),7.84(s,1H),4.60(dd,J=8.0,3.9Hz,1H),4.00(dd,J=11.4,4.1Hz,2H),3.48(d,J=11.9Hz,2H),2.51(s,3H),2.29(dd,J=12.3,4.3Hz,2H)。
example 3
This example provides a pyrimidine derivative T-03, which is synthesized in substantially the same manner as in example 1, except that:
by usingAlternative embodiment 1 +.>Adopts->Alternative embodiment 1 +.>Thereby preparing pyrimidine derivative->
Pyrimidine derivative T-03 was detected as follows:
LCMS:(MS-ESI,m/z):[M+H] + =352。 1 H NMR:(400MHz,DMSO-d6,ppm):δ8.92(s,1H),
8.87(s,1H),8.64(s,1H),8.41(s,1H),7.90(s,1H),4.61(s,1H),3.98(s,2H),3.56(s,2H),2.55(s,3H),2.21(d,J=7.8Hz,2H),2.00(s,2H)。
example 4
This example provides a pyrimidine derivative T-04, which is synthesized in substantially the same manner as in example 1, except that:
by usingAlternative embodiment 1 +.>Adopts->Alternative embodiment 1 +.>Thereby preparing pyrimidine derivative->
Pyrimidine derivative T-04 was detected as follows:
LCMS:(MS-ESI,m/z):[M+H] + =350。 1 H NMR:(400MHz,DMSO-d6,ppm):δ9.14(s,1H),
8.92(s,1H),8.36(s,1H),8.35(s,1H),7.70(s,1H),4.56-4.53(m,1H),3.99-3.95(m,2H),3.47(s,2H),2.37(s,3H),2.17(dd,J=12.1,4.1Hz,1H),1.96(d,J=10.1Hz,1H)。
example 5
This example provides a pyrimidine derivative T-05, which is synthesized in substantially the same manner as in example 1, except that:
Pyrimidine derivative T-05 was detected as follows:
LCMS:(MS-ESI,m/z):[M+H] + =380。 1 H NMR:(400MHz,DMSO-d6,ppm):δ9.11(s,1H),
8.72(s,1H),8.31(s,1H),8.05(s,1H),7.39(s,1H),4.61(s,1H),3.98(s,2H),3.56(s,2H),2.55(s,3H),2.21(d,J=7.8Hz,2H),2.00(s,2H)。
example 6
This example provides a pyrimidine derivative T-06, which is synthesized in substantially the same manner as in example 1, except that:
by usingAlternative embodiment 1 +.>Adopts->Alternative embodiment 1 +.>Thereby preparing pyrimidine derivative->
Pyrimidine derivative T-06 was detected as follows:
LCMS:(MS-ESI,m/z):[M+H] + =392。 1 H NMR:(400MHz,DMSO-d6,ppm):δ9.04(s,1H),
8.82(s,1H),8.16(s,1H),7.95(s,1H),7.65(s,1H),4.57-4.51(m,1H),3.91-3.85(m,2H),3.47(m,2H),2.51(s,3H),2.31(m,2H),2.16(dd,J=11.3,3.1Hz,2H),1.46(m,J=10.1Hz,4H).
product effect test
1. In vitro detection of enzymatic Activity assay for DNA-PK inhibitors
The inhibition of DNA-PK by compounds was examined using a DNA-PK kinase kit, and the specific procedures were as follows:
1. melting DNA-dependent protein Kinase, DNA-dependent protein Kinase peptide substrate (10 mg/mL), ATP (contained in ADP-Glo Kinase Assay kit) on ice, and placing the above reagents on ice all the time in the experimental process, wherein the unused stock solution needs to be split-packed and stored, so as to avoid repeated freeze thawing;
2. taking pyrimidine derivatives T-01 to T-06 in examples 1-6 as samples to be tested, taking DNA-PK inhibitor (code AZD 7648) of the company of Ashikan as a positive sample, dissolving by using 1 Xbuffer (assay buffer) containing 5% DMSO, and adding 1 mu L/well into a microplate; blank control 1 Xbuffer (assay buffer) was added to the microplate at 1. Mu.L/well; the specific structure of the DNA-PK inhibitor AZD7648 is shown below:
after complete solubilization of the DNA-dependent protein kinase, the enzyme solution was added to the microplate at 2. Mu.L/well after dilution to 2.5 unit/. Mu.L with 1 Xbuffer, and the 1 Xbuffer was added to the blank wells at 2. Mu.L/well, and the microplate was centrifuged at 1000 rpm for 1 minute.
4. Preparing a mixed solution of a substrate and ATP: diluting the DNA-dependent protein kinase peptide substrate (10 mg/mL) with 1 Xbuffer solution, adding ATP to make the concentration of ATP 125 mu M and the concentration of the DNA-dependent protein kinase peptide substrate 0.5 mu g/mu L, and placing the mixed solution of the substrate and ATP on ice for later use;
5. adding a mixed solution of a substrate and ATP into a microplate at a concentration of 2 mu L/well, centrifuging the microplate at 1000 revolutions for 1 minute, wherein the concentration of the DNA-dependent protein kinase peptide substrate is 0.2 mu g/mu L, the concentration of ATP is 50 mu M, and the concentration of DMSO is 1%; sealing the membrane by a microplate, and incubating at 25 ℃ for 60min;
ADP-GloTM reagent and Kinase Detection require equilibration to room temperature prior to use;
after the incubation is finished, adding an ADP-GloTM reagent into a microplate at a concentration of 5 mu L/hole, centrifuging the microplate at 1000 revolutions for 1 minute, sealing the microplate, and then placing the microplate at 25 ℃ for incubation for 40 minutes;
7. after the incubation is finished, adding Kinase Detection into a microplate at 10 mu L/hole, centrifuging the microplate at 1000 revolutions for 1 minute, sealing the microplate, and then placing the microplate at 25 ℃ for incubation for 30 minutes; after the incubation is finished, luminescence detection is performed by using Nivo, and Luminescence value (RLU) is read;
8. and (3) calculating the enzyme activity rate:
enzyme activity% = (RLU (sample) -RLU (blank))/(RLU (1% dmso) -RLU (blank))) ×100%
The results of the binding force experiment between the DNA-PK inhibitor and the protein are shown in Table 1.
TABLE 1 determination of enzymatic Activity of DNA-PK inhibitors
As is clear from Table 1, the pyrimidine derivatives in examples 1 to 6 of the present invention all have the effect of inhibiting DNA-PK kinase, and a part of the pyrimidine derivatives have the activity equivalent to or better than AZD7648.
2. MTT cytotoxicity test (LoVo cell)
The inhibition of LoVo cell (human colon cancer cell) growth by pyrimidine derivatives of examples 1-6 was determined using MTT assay. The experimental procedure was as follows:
LoVo cells were seeded at about 5000 cells/well in 96-well plates and incubated at 37℃for 24h. The pyrimidine derivatives of examples 1 to 6 were diluted in a serum-free medium and then added to 96-well plates at a dose of 50. Mu.L/well. After 48h of drug treatment, 10. Mu.L MTT solution was added to each well and incubated for 4h at 37 ℃. The supernatant was carefully aspirated, 150 μl DMSO was added to each well, and gently shaken to dissolve the formazan. OD value was measured with an ELISA reader at 570nm of detection wavelength within 1 h. Analytical calculations were performed using Graphpad Prism software. Inhibition ratio = (100-OD Sample of /OD Solvent(s) ) X100%, where OD Sample of For absorbance values detected after addition of each concentration of the test substance, OD Solvent(s) Absorbance values detected for vehicle group (vehicle added, no test substance added). The positive control was a DNA-PK inhibitor from the company Aspirikang, code AZD7648. The results of the cytotoxicity test of each compound on LoVo cells are shown in table 2.
Table 2 results of the cytotoxicity test of each Compound against LoVo cells
As shown in Table 2, the pyrimidine derivatives in examples 1-6 have a good inhibitory effect on human colon cancer cells, and exhibit a good anti-colonic tumor effect.
3. MTT cytotoxicity test (U373 cell)
The inhibition of the growth of U373 cancer cells (U373 astrocytes) by pyrimidine derivatives of examples 1-6 was determined using the MTT assay. The experimental procedure was as follows:
LoVo cells were seeded at about 5000 cells/well in 96-well plates and incubated at 37℃for 24h. The pyrimidine derivatives of examples 1 to 6 were diluted in a serum-free medium and then added to 96-well plates at a dose of 50. Mu.L/well. After 48h of drug treatment, 10. Mu.L MTT solution was added to each well and incubated for 4h at 37 ℃. The supernatant was carefully aspirated and 150. Mu.L of DMS was added to each wellO, gently shake to dissolve formazan. OD value was measured with an ELISA reader at 570nm of detection wavelength within 1 h. Analytical calculations were performed using Graphpad Prism software. Inhibition ratio = (100-OD Sample of /OD Solvent(s) ) X100%, where OD Sample of For absorbance values detected after addition of each concentration of the test substance, OD Solvent(s) Absorbance values detected for vehicle group (vehicle added, no test substance added). The positive control was a DNA-PK inhibitor from the company Aspirikang, code AZD7648. The results of the cytotoxicity test on U373 cancer cells of each compound are shown in table 3.
Table 3 results of the cytotoxicity test of each Compound against LoVo cells
As shown in Table 2, the pyrimidine derivatives in examples 1 to 6 have a good inhibitory effect on U373 astroglioma cells, and exhibit a good glioma-resistant effect.
4. Effects of DNA-PK inhibitors and irradiation combinations on U373 cancer cells (U373 astroglioma cells)
It is known that the combination of the DNA-PK inhibitor and the irradiation may exert the irradiation sensitization effect, so that the pyrimidine derivatives in examples 1 to 6 are combined with the irradiation and the inhibition effect on U373 cancer cells (U373 astroglioma cells) is examined, and the experimental method and steps are as follows:
cell line U373 at 37℃with 5% CO 2 Is cultured in an incubator, and cells in a logarithmic growth phase are periodically passaged and plated. U373 was inoculated at 5000 cells/well into 96-well plates and incubated at 37℃for 24h. The pyrimidine derivatives of examples 1 to 6 were diluted in a serum-free medium and then added to 96-well plates at a dose of 50. Mu.L/well. After the dosing procedure was completed, the 96-well plate was placed in an incubator, 1 hour later, placed in a RadSource 2000X-ray instrument, irradiated at an irradiation intensity of 2.4Gy, and the 96-well cell plate was returned to the incubator for 9 days after the irradiation was completed. Cell activity assay using CellTiter-Glo luminescence method, the following formula was used to calculate assay compoundsInhibition Rate (IR): IR (%) = (1- (RLU) Compounds of formula (I) –RLU Blank control )/(RLU Vehicle control –RLU Blank control ) Inhibition IC of 100% of the resulting compound 50 The results are shown in Table 4.
TABLE 4 inhibition Activity of DNA-PK inhibitors and irradiation combinations on U373 cell growth
As shown in Table 4, the pyrimidine derivatives of examples 1 to 6 also have a stronger inhibitory effect on U373 cancer cells when used in combination with irradiation, and the combination of both shows a good synergistic effect, as compared with AZD7648.
5. In vivo pharmacokinetics in rats
Healthy SD rats were randomly divided into 6 groups of 3 each. Plasma kinetics studies were performed in each group of rats with a single intragastric administration of the pyrimidine derivative of example 5, the pyrimidine derivative of example 6, and AZD7648. The plasma dynamics characteristics of the drug in the rat body are analyzed, including the exposure degree, absorption characteristics and the like of the original drug.
The oral administration dose is 5mg/kg, blood is collected at 7.5min, 15min, 30min, 1h, 2h, 4h, 8h and 24h respectively, EDTA is used as anticoagulant for whole blood collection, centrifugation is carried out at 4 ℃ and 10000 revolutions per minute for 1 min, blood plasma is separated in 1h, the blood is preserved at-20 ℃ to be detected, and the blood collection to centrifugation process is operated under ice bath condition. Sucking 30 mu L of plasma sample to be detected, adding 300 mu L of acetonitrile solution containing an internal standard (20 ng/mL of apixaban), shaking and uniformly mixing for 5 minutes, centrifuging at 13000rpm for 10 minutes, taking 80 mu L of supernatant, adding 80 mu L of ultrapure water for dilution, uniformly mixing, sucking 2 mu L of the supernatant for liquid chromatography-mass spectrometry analysis and determination, and calculating the drug generation parameters. The test results are shown in Table 5.
Each of table 5 represents the pharmacokinetic parameters of a compound
As can be seen from Table 5, the pyrimidine compounds of examples 5-6 have good absorption in the drug generation and have significant pharmacokinetic advantages.
While the embodiments of the present invention have been described in detail, the present invention is not limited to the above embodiments, and various changes can be made without departing from the spirit of the present invention within the knowledge of those skilled in the art. Furthermore, embodiments of the invention and features of the embodiments may be combined with each other without conflict.
Claims (10)
1. A pyrimidine derivative or pharmaceutically acceptable salts and stereoisomers thereof, which is characterized in that the pyrimidine derivative has a structural general formula shown in (I):
wherein X, Y and Z are each independently selected from CH, N; r is R 1 Selected from the following substituted or unsubstituted: c (C) 5 -C 12 Saturated or unsaturated carboheterocyclyl, C 5 -C 12 Saturated or unsaturated spiroheterocyclyl, C 5 -C 12 Saturated or unsaturated fused heterocyclic groups, wherein the substituents refer to one or more groups selected from the group consisting of: hydroxy, halogen, cyano, amino.
5. use of a pyrimidine derivative according to any one of claims 1 to 3, or a pharmaceutically acceptable salt, stereoisomer thereof, in the preparation of an antitumor drug.
6. The use according to claim 5, wherein the tumour is selected from colon cancer, lung cancer, ovarian cancer, endometrial cancer, pancreatic cancer, head and neck cancer, oesophageal cancer, breast cancer, colorectal cancer, lymphoma, leukaemia, synovial sarcoma, melanoma, liver cancer, stomach cancer, bladder cancer, squamous cell carcinoma, medulloblastoma, renal cancer or glioma.
7. An antitumor drug comprising as a first therapeutic agent the pyrimidine derivative of any one of claims 1 to 3 or a pharmaceutically acceptable salt, stereoisomer thereof.
8. The antineoplastic agent of claim 7, further comprising a pharmaceutically acceptable adjuvant.
9. The antineoplastic agent of claim 8, wherein the pharmaceutically acceptable excipients comprise at least one of cellulose and its derivatives, gelatin, talc, solid lubricants, calcium sulfate, vegetable oils, polyols, emulsifiers, wetting agents, colorants, flavors, stabilizers, antioxidants, preservatives, or water.
10. The antineoplastic agent of claim 7, wherein said antineoplastic agent further comprises a second therapeutic agent, the second therapeutic agent is selected from the group consisting of oxidastine, lu Kapa, nilapamide, methotrexate, capecitabine, gemcitabine, doxifluridine, pemetrexed disodium, pazopanib, imatinib, erlotinib, lapatinib, gefitinib, vandetanib, herceptin, bevacizumab, rituximab, trastuzumab, paclitaxel, vinorelbine, docetaxel, doxorubicin, hydroxycamptothecin, mitomycin, epirubicin, pirarubicin, bleomycin, letrozole, tamoxifen, fulvestrant, tratrelin, fluzaorelin, leuprolide, alfuzosin, and fluvalvulgare at least one of ifosfamide, busulfan, cyclophosphamide, carmustine, nimustine, semustine, nitrogen mustard, marflange, buflunine, carboplatin, cisplatin, oxaliplatin, cisplatin, topotecan, camptothecine, topotecan, everolimus, siromosi, tetroxide, 6-mercaptopurine, 6-thioguanine, azathioprine, biotin D, daunorubicin, doxorubicin, mitoxantrone, bleomycin, plicamycin or aminoglutethimide, nivolumab, pemetuzumab, ipilimumab, avermectin, dimetuzumab, alt Zhu Shan antibody, pirimuzumab.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310154871.8A CN116239610B (en) | 2023-02-23 | 2023-02-23 | Pyrimidine derivative, preparation method thereof and application thereof in preparation of antitumor drugs |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310154871.8A CN116239610B (en) | 2023-02-23 | 2023-02-23 | Pyrimidine derivative, preparation method thereof and application thereof in preparation of antitumor drugs |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116239610A true CN116239610A (en) | 2023-06-09 |
CN116239610B CN116239610B (en) | 2024-01-16 |
Family
ID=86627372
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310154871.8A Active CN116239610B (en) | 2023-02-23 | 2023-02-23 | Pyrimidine derivative, preparation method thereof and application thereof in preparation of antitumor drugs |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116239610B (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018011999A1 (en) * | 2016-07-15 | 2018-01-18 | 株式会社小松製作所 | Work vehicle, remote diagnostic system, and remote diagnostic method |
WO2021136463A1 (en) * | 2019-12-31 | 2021-07-08 | 成都百裕制药股份有限公司 | Purine derivative and medical use thereof |
CN113924305A (en) * | 2019-05-27 | 2022-01-11 | 迪哲(江苏)医药股份有限公司 | DNA-dependent protein kinase inhibitors |
CN114634521A (en) * | 2020-12-15 | 2022-06-17 | 首药控股(北京)股份有限公司 | DNA-PK selective inhibitor and preparation method and application thereof |
CN114656487A (en) * | 2020-12-22 | 2022-06-24 | 江苏恒瑞医药股份有限公司 | Condensed pyrimidine compound, preparation method and medical application thereof |
-
2023
- 2023-02-23 CN CN202310154871.8A patent/CN116239610B/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018011999A1 (en) * | 2016-07-15 | 2018-01-18 | 株式会社小松製作所 | Work vehicle, remote diagnostic system, and remote diagnostic method |
CN113924305A (en) * | 2019-05-27 | 2022-01-11 | 迪哲(江苏)医药股份有限公司 | DNA-dependent protein kinase inhibitors |
WO2021136463A1 (en) * | 2019-12-31 | 2021-07-08 | 成都百裕制药股份有限公司 | Purine derivative and medical use thereof |
CN114634521A (en) * | 2020-12-15 | 2022-06-17 | 首药控股(北京)股份有限公司 | DNA-PK selective inhibitor and preparation method and application thereof |
CN114656487A (en) * | 2020-12-22 | 2022-06-24 | 江苏恒瑞医药股份有限公司 | Condensed pyrimidine compound, preparation method and medical application thereof |
Non-Patent Citations (1)
Title |
---|
ZONGBAO DING, ET AL.: "Discovery of novel 7, 8-dihydropteridine-6(5H)-one-based DNA-PK inhibitors as potential anticancer agents via scaffold hopping strategy", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》, vol. 237, pages 114401 * |
Also Published As
Publication number | Publication date |
---|---|
CN116239610B (en) | 2024-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3385262B1 (en) | 4-(3h-indol-5-yl)-n-(pyridin-2-yl)pyrimidin-2-amine derivatives as protein kinase inhibitors, preparation method and medical use thereof | |
EP4144732A1 (en) | Benzothiazolyl biaryl compound, and preparation method and use | |
IL267158A (en) | Amino-triazolopyridine compounds and their use in treating cancer | |
EP3068785A1 (en) | Substituted 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine derivatives as casein kinase 1 d/e inhibitors | |
JP2019500413A5 (en) | ||
KR102660196B1 (en) | Kinase inhibitors that are substituted condensed heteroaryl compounds and their applications | |
JP2021511353A (en) | Substituted pyrazolo [1,5-a] pyrimidine macrocycle | |
WO2021043208A1 (en) | 3, 5-disubstituted pyrazole compounds as kinase inhibitors and uses thereof | |
WO2011103007A2 (en) | 10'-fluorinated vinca alkaloids provide enhanced biological activity against mdr cancer cells | |
CN113527300B (en) | Bruton's tyrosine protein kinase inhibitor | |
JP6970684B2 (en) | Sulfonamide derivative with coumarin skeleton | |
US11547703B2 (en) | Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereof | |
CN107266466B (en) | The application of scutellarin biotinylated probe and correlation PKM2 kinase inhibitor | |
CN116239610B (en) | Pyrimidine derivative, preparation method thereof and application thereof in preparation of antitumor drugs | |
CN115322209B (en) | Tri-fused ring compounds as DNA-PK inhibitors | |
CN111961084A (en) | Lung cancer cell inhibitor and preparation method thereof | |
CN111333655B (en) | Triazolopyrimidine compound and preparation method and application thereof | |
CN111393500B (en) | Oleanolic acid derivative with conjugated diene structure C ring and preparation method and application thereof | |
JP7182548B2 (en) | Azaindenoisoquinoline compounds and uses thereof | |
CN115043878B (en) | Biotinylated gold (I) complex with tumor targeting function, and preparation method and application thereof | |
Koračak et al. | Novel artesunate–pyrimidine-based hybrids with anticancer potential against multidrug-resistant cancer cells | |
CN112812145B (en) | Benzimidazole derivative BI293 and preparation method and application thereof | |
CN109438481B (en) | Bis-fluoroquinolone oxadiazole urea derivative containing N-methylmoxifloxacin and preparation method and application thereof | |
CN109400627B (en) | Bis-fluoroquinolone oxadiazole urea derivative containing N-methyl lomefloxacin and preparation method and application thereof | |
CN109369677B (en) | Bis-fluoroquinolone oxadiazole urea N-methyl ciprofloxacin derivative and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |